Clinical efficacy of pseudomonas aeruginosa injection combined with endostar in the treatment of malignant pleural effusion: a randomized trial.

OBJECTIVE

This study aims to investigate the therapeutic effects of combining pseudomonas aeruginosa injection (PAI) with endostar on patients with malignant pleural effusion and ascites.

METHODS

In this prospective study, a total of 105 patients with malignant pleural effusion and ascites admitted to our hospital from January 2019 to April 2022 were selected as research subjects. Among them, 35 patients treated with PAI combined with endostar were enrolled in the observation group, while 35 patients treated with PAI and another 35 patients treated with endostar were enrolled in the control groups. The clinical effectiveness and safety of all three groups were compared, and their relapse-free survival was examined over a period of 90 days.

RESULTS

After treatment, the remission rate and the relapse-free survival of the observation group were higher than those of the control groups (P < 0.05), but there was no difference between the control groups (P > 0.05). The main adverse effect observed was fever, which was more common in the PAI combined with endostar group than in the endostar-only group (P < 0.05).

CONCLUSION

The clinical treatment of malignant pleural effusion and ascites can be improved by combining pseudomonas aeruginosa injection with endostar. This combination can increase the relapse-free survival of patients and improve the overall safety of treatment.